{"id":801253,"date":"2025-01-15T16:11:58","date_gmt":"2025-01-15T21:11:58","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-announces-sale-of-univerxome-subsidiary\/"},"modified":"2025-01-15T16:11:58","modified_gmt":"2025-01-15T21:11:58","slug":"serina-therapeutics-announces-sale-of-univerxome-subsidiary","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-announces-sale-of-univerxome-subsidiary\/","title":{"rendered":"Serina Therapeutics Announces Sale of UniverXome Subsidiary"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>&#8211; Transaction eliminates $11.2 million in debt, strengthening financial position &#8211;<\/em>\n      <\/p>\n<p align=\"justify\">\n        <strong>HUNTSVILLE, AL, Jan.  15, 2025  (GLOBE NEWSWIRE) &#8212; <\/strong>Serina Therapeutics Inc. (\u201cSerina\u201d) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform<sup>\u2122<\/sup> drug delivery technology, today announced the sale of its UniverXome subsidiary. The transaction was finalized on December 23, 2024 and eliminated $11.2 million in associated subsidiary-level debt, positioning Serina with a debt-free balance sheet heading into 2025.<\/p>\n<p align=\"justify\">The UniverXome subsidiary was established prior to Serina\u2019s reverse merger with AgeX Therapeutics in March 2024 to own the legacy assets of the predecessor company.<\/p>\n<p align=\"justify\">Steve Ledger, CEO of Serina, commented, \u201cThis transaction underscores our commitment to maintaining a focused operational strategy centered on advancing SER-252, our lead candidate for advanced Parkinson\u2019s disease, into clinical development. By achieving a debt-free balance sheet, we have strengthened our financial foundation, enabling us to accelerate our patient-driven mission. Additionally, this allows us to further explore the broad potential of our POZ Platform<sup>\u2122<\/sup> to address unmet needs across multiple therapeutic modalities, including small molecules, lipid nanoparticles (LNPs), and antibody-drug conjugates (ADCs).\u201d<\/p>\n<p align=\"justify\">\n        <strong>About SER-252 POZ apomorphine<\/strong>\n      <\/p>\n<p align=\"justify\">SER-252 is an investigational apomorphine therapy developed with Serina\u2019s POZ platform and designed to provide continuous dopaminergic stimulation (CDS). CDS has been shown to reduce the severity of levodopa-related motor complications (dyskinesia) in Parkinson\u2019s disease. Preclinical studies support the potential of SER-252 to provide CDS without skin reactions. Serina plans to advance SER-252 to clinical testing in 2025.<\/p>\n<p align=\"justify\">\n        <strong>About the POZ Platform<\/strong><br \/>\n        <sup><br \/>\n          <strong>\u2122<\/strong><br \/>\n        <\/sup>\n      <\/p>\n<p align=\"justify\">Serina\u2019s proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Serina\u2019s POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. The therapeutic agents in Serina\u2019s product candidates are typically well-understood and marketed drugs that are effective but may be limited by pharmacokinetic profiles that can include toxicity, side effects and short half-life. Serina believes that by using POZ technology, drugs with narrow therapeutic windows can be designed to maintain more desirable and stable levels in the blood.<\/p>\n<p align=\"justify\">Serina\u2019s POZ platform delivery technology has potential for use across a broad range of payloads and indications. Serina intends to advance additional applications of the POZ platform via out-licensing, co-development, or other partnership arrangements, including the non-exclusive license agreement with Pfizer, Inc. to use Serina\u2019s POZ polymer technology for use in lipid nanoparticle drug (LNP) delivery formulations.<\/p>\n<p align=\"justify\">\n        <strong>About Serina Therapeutics<\/strong>\n      <\/p>\n<p align=\"justify\">Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina\u2019s POZ Platform<sup>\u2122<\/sup>\u00a0provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology.<\/p>\n<p>For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8KMC-OofeWXLOY9yiklsDQ6ha2TCa32P3TL7XbXOVPjqHqXxKrE6Gwc2p_c8zkmc96s0QcKWzFW2ImxNZAEMmo6mwhKqejxOEAkVBzCei4oH8RJb1d9PYfmg_X81082CEXQISw5YwdTTX1YzVUK3aioKZD_HcDo7sX2KjXVgd8y5tuhzmHLl4JzJ_nbGxs3L8pnVtW9BhYLrZ5omrfrSfYhjYOvJxYQeLblSizTxZadS2HFw1o2QkUOfgmEeOCTesRFa1a718PWfnvmHxsI8_jCx7UHefHC2X7Bov_fxBkXTgxDl9R8dWeZ3hIp79jVy\" rel=\"nofollow\" target=\"_blank\"><u>https:\/\/serinatherapeutics.com<\/u><\/a>.<\/p>\n<p>\n        <strong>Cautionary Statement Regarding Forward-Looking Statement<\/strong>\n      <\/p>\n<p align=\"justify\">This release contains forward-looking statements within the meaning of federal securities laws. These statements are based on management\u2019s current expectations, plans, beliefs or forecasts for the future, and are subject to uncertainty and changes in circumstances. Any express or implied statements in this press release that are not statements of historical fact, including statements about the potential of Serina\u2019s POZ polymer technology, are forward-looking statements that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and\/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and\/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any applications may be filed for any drug or vaccine candidates in any jurisdictions; whether and when regulatory authorities may approve any potential applications that may be filed for any drug or vaccine candidates in any jurisdictions, which will depend on a myriad of factors, including making a determination as to whether the product\u2019s benefits outweigh its known risks and determination of the product\u2019s efficacy and, if approved, whether any such drug or vaccine candidates will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and\/or other matters that could affect the availability or commercial potential of any drug or vaccine candidates; and competitive developments. These risks as well as other risks are more fully discussed in the company\u2019s Annual Report on Form 10-K for the year ended December 31, 2023, the company\u2019s Current Report on Form 8-K that was filed with the SEC on April 1, 2024, and the company\u2019s other periodic reports and documents filed from time to time with the SEC.<\/p>\n<p align=\"justify\">The information contained in this release is as of the date hereof, and Serina assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.<\/p>\n<p>\n        <strong>For inquiries, please contact:<\/strong><br \/>\n        <br \/>Stefan Riley<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xRkjj2zYXk3fFG4pvkgcq1ScgIF8XZAsM59waH5kePehGtGxcv6zAvkyQKR3bR3gUoTx8M2j_zRClboadolCxrD8upKBiJrnXmj7zoNMhO-eSWhd2j0l0QrlvkvfY-3j\" rel=\"nofollow\" target=\"_blank\"><strong>sriley@serinatherapeutics.com<\/strong><\/a><br \/>(256) 327-9630<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzMjY4NyM2Njk2MTE0IzUwMDExOTk2NQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/OGMxOWJkYTAtZmMwNy00ZDE3LTllMjUtNDVmMzI3M2E1MTZjLTUwMDExOTk2NQ==\/tiny\/Serina-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>&#8211; Transaction eliminates $11.2 million in debt, strengthening financial position &#8211; HUNTSVILLE, AL, Jan. 15, 2025 (GLOBE NEWSWIRE) &#8212; Serina Therapeutics Inc. (\u201cSerina\u201d) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform\u2122 drug delivery technology, today announced the sale of its UniverXome subsidiary. The transaction was finalized on December 23, 2024 and eliminated $11.2 million in associated subsidiary-level debt, positioning Serina with a debt-free balance sheet heading into 2025. The UniverXome subsidiary was established prior to Serina\u2019s reverse merger with AgeX Therapeutics in March 2024 to own the legacy assets of the predecessor company. Steve Ledger, CEO of Serina, commented, \u201cThis transaction underscores our commitment to maintaining a focused operational strategy centered on advancing SER-252, our lead &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-announces-sale-of-univerxome-subsidiary\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Serina Therapeutics Announces Sale of UniverXome Subsidiary&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-801253","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Serina Therapeutics Announces Sale of UniverXome Subsidiary - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-announces-sale-of-univerxome-subsidiary\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Serina Therapeutics Announces Sale of UniverXome Subsidiary - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"&#8211; Transaction eliminates $11.2 million in debt, strengthening financial position &#8211; HUNTSVILLE, AL, Jan. 15, 2025 (GLOBE NEWSWIRE) &#8212; Serina Therapeutics Inc. (\u201cSerina\u201d) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform\u2122 drug delivery technology, today announced the sale of its UniverXome subsidiary. The transaction was finalized on December 23, 2024 and eliminated $11.2 million in associated subsidiary-level debt, positioning Serina with a debt-free balance sheet heading into 2025. The UniverXome subsidiary was established prior to Serina\u2019s reverse merger with AgeX Therapeutics in March 2024 to own the legacy assets of the predecessor company. Steve Ledger, CEO of Serina, commented, \u201cThis transaction underscores our commitment to maintaining a focused operational strategy centered on advancing SER-252, our lead &hellip; Continue reading &quot;Serina Therapeutics Announces Sale of UniverXome Subsidiary&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-announces-sale-of-univerxome-subsidiary\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-15T21:11:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzMjY4NyM2Njk2MTE0IzUwMDExOTk2NQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/serina-therapeutics-announces-sale-of-univerxome-subsidiary\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/serina-therapeutics-announces-sale-of-univerxome-subsidiary\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Serina Therapeutics Announces Sale of UniverXome Subsidiary\",\"datePublished\":\"2025-01-15T21:11:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/serina-therapeutics-announces-sale-of-univerxome-subsidiary\\\/\"},\"wordCount\":887,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/serina-therapeutics-announces-sale-of-univerxome-subsidiary\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMzMjY4NyM2Njk2MTE0IzUwMDExOTk2NQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/serina-therapeutics-announces-sale-of-univerxome-subsidiary\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/serina-therapeutics-announces-sale-of-univerxome-subsidiary\\\/\",\"name\":\"Serina Therapeutics Announces Sale of UniverXome Subsidiary - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/serina-therapeutics-announces-sale-of-univerxome-subsidiary\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/serina-therapeutics-announces-sale-of-univerxome-subsidiary\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMzMjY4NyM2Njk2MTE0IzUwMDExOTk2NQ==\",\"datePublished\":\"2025-01-15T21:11:58+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/serina-therapeutics-announces-sale-of-univerxome-subsidiary\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/serina-therapeutics-announces-sale-of-univerxome-subsidiary\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/serina-therapeutics-announces-sale-of-univerxome-subsidiary\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMzMjY4NyM2Njk2MTE0IzUwMDExOTk2NQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMzMjY4NyM2Njk2MTE0IzUwMDExOTk2NQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/serina-therapeutics-announces-sale-of-univerxome-subsidiary\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Serina Therapeutics Announces Sale of UniverXome Subsidiary\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Serina Therapeutics Announces Sale of UniverXome Subsidiary - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-announces-sale-of-univerxome-subsidiary\/","og_locale":"en_US","og_type":"article","og_title":"Serina Therapeutics Announces Sale of UniverXome Subsidiary - Market Newsdesk","og_description":"&#8211; Transaction eliminates $11.2 million in debt, strengthening financial position &#8211; HUNTSVILLE, AL, Jan. 15, 2025 (GLOBE NEWSWIRE) &#8212; Serina Therapeutics Inc. (\u201cSerina\u201d) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform\u2122 drug delivery technology, today announced the sale of its UniverXome subsidiary. The transaction was finalized on December 23, 2024 and eliminated $11.2 million in associated subsidiary-level debt, positioning Serina with a debt-free balance sheet heading into 2025. The UniverXome subsidiary was established prior to Serina\u2019s reverse merger with AgeX Therapeutics in March 2024 to own the legacy assets of the predecessor company. Steve Ledger, CEO of Serina, commented, \u201cThis transaction underscores our commitment to maintaining a focused operational strategy centered on advancing SER-252, our lead &hellip; Continue reading \"Serina Therapeutics Announces Sale of UniverXome Subsidiary\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-announces-sale-of-univerxome-subsidiary\/","og_site_name":"Market Newsdesk","article_published_time":"2025-01-15T21:11:58+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzMjY4NyM2Njk2MTE0IzUwMDExOTk2NQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-announces-sale-of-univerxome-subsidiary\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-announces-sale-of-univerxome-subsidiary\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Serina Therapeutics Announces Sale of UniverXome Subsidiary","datePublished":"2025-01-15T21:11:58+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-announces-sale-of-univerxome-subsidiary\/"},"wordCount":887,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-announces-sale-of-univerxome-subsidiary\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzMjY4NyM2Njk2MTE0IzUwMDExOTk2NQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-announces-sale-of-univerxome-subsidiary\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-announces-sale-of-univerxome-subsidiary\/","name":"Serina Therapeutics Announces Sale of UniverXome Subsidiary - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-announces-sale-of-univerxome-subsidiary\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-announces-sale-of-univerxome-subsidiary\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzMjY4NyM2Njk2MTE0IzUwMDExOTk2NQ==","datePublished":"2025-01-15T21:11:58+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-announces-sale-of-univerxome-subsidiary\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-announces-sale-of-univerxome-subsidiary\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-announces-sale-of-univerxome-subsidiary\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzMjY4NyM2Njk2MTE0IzUwMDExOTk2NQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzMjY4NyM2Njk2MTE0IzUwMDExOTk2NQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-announces-sale-of-univerxome-subsidiary\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Serina Therapeutics Announces Sale of UniverXome Subsidiary"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/801253","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=801253"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/801253\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=801253"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=801253"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=801253"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}